Key Takeaways Hologic's Breast Health revenues improved in Q3 and are expected to return to growth in Q4.Hologic boosted focus with a new leadership team, revamped salesforce and a gantry upgrade strategy.Hologic's HIV testing business in Africa is hurt by reduced USAID funding, limiting growth overseas.After a stretch of soft performance, Hologic’s (HOLX) latest quarterly results signaled progress across multiple fronts. The Breast Health business, which has drawn much attention from investors following a ...